Compare AENT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | CNTX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | 697 | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.0M | 283.9M |
| IPO Year | N/A | 2021 |
| Metric | AENT | CNTX |
|---|---|---|
| Price | $5.90 | $2.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $6.60 |
| AVG Volume (30 Days) | 23.1K | ★ 610.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $0.52 |
| 52 Week High | $8.80 | $3.62 |
| Indicator | AENT | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 61.86 |
| Support Level | $5.19 | $2.74 |
| Resistance Level | $7.53 | $2.90 |
| Average True Range (ATR) | 0.66 | 0.17 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 25.83 | 72.46 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.